The conducted studies demonstrated a significant advantage of the combined therapy using the juglone-based Thiopyrano[2,3-d]Thiazole derivative LES-6400 and the anti-HER2 antibody (trastuzumab) over monotherapies with these agents in the treatment of AGS gastric cancer. The gene discussed is ERBB2; the disease is gastric cancer.